Literature DB >> 18927504

Resist or die: FOXO transcription factors determine the cellular response to chemotherapy.

Ana R Gomes1, Jan J Brosens, Eric W-F Lam.   

Abstract

FOXO transcription factors are important regulators of cell fate decisions, capable of inducing cell death as well as promoting cell survival and resistance to environmental stress. As is the case for many cancers, apoptosis of leukaemic cells in response to chemotherapeutic drugs such as doxorubicin is dependent upon FOXO activation. Surprisingly, prolonged FOXO activity paradoxically promotes drug-resistance in leukaemia by enhancing the expression of critical signal intermediates that drive the activity of the Class 1A PI3-K/Akt survival pathway. Additionally, under continuous stress, FOXO factors also induce the expression of genes important for drug efflux, antioxidant defence, and DNA damage repair. Thus, the same effector molecules, FOXOs, are responsible for not only the initial therapeutic response to cancer drugs but also the subsequent acquisition of resistance. This emerging evidence demonstrates that FOXO factors have a dual role in stress response and function at the axis of cancer drug sensitivity and resistance. Nevertheless, the mechanism that allows FOXO to escape the negative control of the PI3-K/Akt pathway in response to persistent cytotoxic stress and to switch its control from pro-apoptotic to pro-survival target genes is not well understood but likely to involve a series of defined post-translational protein modifications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18927504     DOI: 10.4161/cc.7.20.6920

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  47 in total

1.  Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer.

Authors:  Yanyuan Wu; Yayha Elshimali; Marianna Sarkissyan; Hezla Mohamed; Sheila Clayton; Jaydutt V Vadgama
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

2.  Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma.

Authors:  Mariana Brait; Enrico Munari; Cynthia LeBron; Maartje G Noordhuis; Shahnaz Begum; Christina Michailidi; Nilda Gonzalez-Roibon; Leonel Maldonado; Tanusree Sen; Rafael Guerrero-Preston; Leslie Cope; Paola Parrella; Vito Michele Fazio; Patrick K Ha; George J Netto; David Sidransky; Mohammad O Hoque
Journal:  Cell Cycle       Date:  2013-02-22       Impact factor: 4.534

Review 3.  Development and maintenance of cancer stem cells under chronic inflammation.

Authors:  Toshihiko Tanno; William Matsui
Journal:  J Nippon Med Sch       Date:  2011       Impact factor: 0.920

Review 4.  Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance.

Authors:  Fung Zhao; Eric W-F Lam
Journal:  Front Med       Date:  2012-11-03       Impact factor: 4.592

5.  Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy.

Authors:  Stephen L Abrams; Linda S Steelman; John G Shelton; William Chappell; Jörg Bäsecke; Franca Stivala; Marco Donia; Ferdinando Nicoletti; Massimo Libra; Alberto M Martelli; James A McCubrey
Journal:  Cell Cycle       Date:  2010-05-15       Impact factor: 4.534

6.  The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.

Authors:  Stephen L Abrams; Linda S Steelman; John G Shelton; Ellis W T Wong; William H Chappell; Jörg Bäsecke; Franca Stivala; Marco Donia; Ferdinando Nicoletti; Massimo Libra; Alberto M Martelli; James A McCubrey
Journal:  Cell Cycle       Date:  2010-05-10       Impact factor: 4.534

7.  β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.

Authors:  Stephan P Tenbaum; Paloma Ordóñez-Morán; Isabel Puig; Irene Chicote; Oriol Arqués; Stefania Landolfi; Yolanda Fernández; José Raúl Herance; Juan D Gispert; Leire Mendizabal; Susana Aguilar; Santiago Ramón y Cajal; Simó Schwartz; Ana Vivancos; Eloy Espín; Santiago Rojas; José Baselga; Josep Tabernero; Alberto Muñoz; Héctor G Palmer
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

8.  FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis.

Authors:  R van Boxtel; C Gomez-Puerto; M Mokry; A Eijkelenboom; K E van der Vos; E E S Nieuwenhuis; B M T Burgering; E W-F Lam; P J Coffer
Journal:  Cell Death Differ       Date:  2013-07-05       Impact factor: 15.828

9.  Phospho-ΔNp63α/microRNA feedback regulation in squamous carcinoma cells upon cisplatin exposure.

Authors:  Yiping Huang; Dafna Kesselman; Darya Kizub; Rafael Guerrero-Preston; Edward A Ratovitski
Journal:  Cell Cycle       Date:  2013-01-23       Impact factor: 4.534

10.  Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.

Authors:  Nandini Dey; Yuliang Sun; Jennifer H Carlson; Hui Wu; Xiaoqian Lin; Brian Leyland-Jones; Pradip De
Journal:  Am J Cancer Res       Date:  2016-03-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.